

# Frequently Asked Questions

## WHAT IS A STUDY DRUG?

A study drug is not yet approved for sale by any government health agency or authority. Clinical research studies (or trials) are used to test the safety and efficacy of a study drug.

## WHAT IS A RESEARCH STUDY?

A research study is designed to evaluate whether a study drug is safe and effective for use in humans. Every study drug goes through the research study process. Participants are given specific medical treatments and researchers closely monitor the results to help determine if the study drug should be approved for wider use. Participants play a very important role in advancing medicine for present and future generations.

## WHAT TYPE OF RESEARCH STUDY IS THE SHIMMER STUDY?

The SHIMMER study is a clinical trial evaluating the safety and effectiveness of the study drug CT1812 in participants with mild to moderate Dementia with Lewy Bodies (DLB).

## IS THERE A COST TO PARTICIPATE IN THE SHIMMER STUDY?

There is no cost to participate in the SHIMMER study. Eligible participants may receive reimbursement for time and travel-related expenses (including long-distance travel). Study-related medications and examinations are offered at no cost to eligible participants.

## HOW CAN I LEARN MORE ABOUT THE STUDY DRUG CT1812 AND THE SHIMMER STUDY?

To learn more, please talk to your doctor. Additional information on this research study can be found by visiting [shimmerDLBstudy.com](http://shimmerDLBstudy.com) or calling 844-292-4100.



LEARN MORE:

[shimmerDLBstudy.com](http://shimmerDLBstudy.com)

ClinicalTrials.gov – NCT # NCT05225415

Contact Information:

**Melanie Elam**  
**University of Kentucky**  
**859-323-1331**

This study is being conducted by:



Cognition Therapeutics, Inc.

2403 Sidney St., Suite 261 Pittsburgh, PA 15203

[cogrx.com](http://cogrx.com)

A RESEARCH STUDY FOR MILD TO MODERATE  
DEMENTIA WITH LEWY BODIES



THE SHIMMER STUDY

TOGETHER WE CAN  
*light the way*

FOR DEMENTIA WITH  
LEWY BODIES RESEARCH.

# What is DEMENTIA WITH LEWY BODIES?

Dementia with Lewy Bodies (DLB) is one of the most common causes of dementia. Lewy Bodies are tiny clumps of abnormal protein particles that accumulate in the brain. In addition to worsening dementia and movement deficiency, patients with DLB endure a wide range of debilitating symptoms including cognitive fluctuations, recurrent visual hallucinations, and sleep disorders. Lewy Bodies are also found in other brain disorders, including Alzheimer's disease and Parkinson's disease dementia.

## ABOUT THE STUDY DRUG CT1812

The study drug, CT1812, is being investigated for the treatment of Dementia with Lewy Bodies. Participants will take two capsules of CT1812 every morning by mouth with food. This study drug will be compared to a placebo. A placebo is a capsule that looks like the study drug but does not contain any active ingredient. By comparing the outcome of people treated with the active study drug versus the placebo, researchers aim to determine if the study drug is effective for treating DLB. In this research study, participants have a 2 out of 3 chance of receiving the study drug CT1812 versus the placebo.

Certain proteins (called  $\alpha$ -synuclein oligomers and amyloid beta oligomers) are believed to bind to brain cells in patients with DLB, leading to symptoms such as worsening dementia and movement deficiency. CT1812 is intended to enter the brain and block these proteins from attaching to brain cells. It is hoped that by blocking these toxic proteins from binding to brain cells, patients with DLB will experience improved symptoms.

In early trials, CT1812 was shown to be safe and well tolerated.

## Why Should I Participate?

### DECIDING TO PARTICIPATE IN THE SHIMMER STUDY MEANS YOU WILL:

- Play an integral role in the advancement of DLB research
- Receive care from a local doctor at no cost to you

## Am I Eligible?

### YOU OR A LOVED ONE MAY QUALIFY IF YOU OR THEY:

- Are between the ages of 50 to 85
- Have been diagnosed with mild to moderate Dementia with Lewy Bodies (DLB)
- Have a caregiver or study partner who is willing and able to attend all study visits and participate in some study assessments
- Have not had a stroke or transient ischemic attack (TIA) within the past 12 months

*There are additional study requirements to participate. A SHIMMER study representative will discuss them with you.*



## ABOUT THE STUDY

### What is the SHIMMER study?

The SHIMMER study is evaluating the study drug, CT1812, in adults ages 50 to 85 with mild to moderate Dementia with Lewy Bodies (DLB).

The purpose of this research study is to learn about the safety of CT1812 and how well you or your loved one tolerate(s) a once-a-day oral dose of CT1812. The study will also test how well CT1812 treats mild to moderate DLB.

## WHAT TO EXPECT FROM THE SHIMMER STUDY

Up to 120 participants will be enrolled in the study.

The total duration of participation in the study, including screening, is approximately 8 months and consists of 12 study visits.

If you take part in the research study, your caregiver must accompany you to all your visits, assist you with taking the study medication in between visits, and help you report how you are feeling at each visit.

Participants will be randomly assigned to 1 of 3 groups in this study:

#### GROUP 1

Will take 100 mg of CT1812 (2 capsules) once daily

#### GROUP 2

Will take 300 mg of CT1812 (2 capsules) once daily

#### GROUP 3

Will take the placebo (2 capsules) once daily